Checkpoint Therapeutics Stock Price Prediction

CKPT Stock  USD 1.58  0.10  6.76%   
The RSI of Checkpoint Therapeutics' share price is below 30 at this time suggesting that the stock is becoming oversold or undervalued. The main point of the Relative Strength Index (RSI) is to track how fast people are buying or selling Checkpoint Therapeutics, making its price go up or down.

Oversold Vs Overbought

22

 
Oversold
 
Overbought
Checkpoint Therapeutics stock price prediction is an act of determining the future value of Checkpoint Therapeutics shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Checkpoint Therapeutics' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Checkpoint Therapeutics and does not consider all of the tangible or intangible factors available from Checkpoint Therapeutics' fundamental data. We analyze noise-free headlines and recent hype associated with Checkpoint Therapeutics, which may create opportunities for some arbitrage if properly timed.
Below are the key fundamental drivers impacting Checkpoint Therapeutics' stock price prediction:
EPS Estimate Next Quarter
(0.38)
EPS Estimate Current Year
(1.12)
EPS Estimate Next Year
(0.20)
Wall Street Target Price
17.25
EPS Estimate Current Quarter
(0.54)
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Checkpoint Therapeutics based on different types of headlines from major news networks to social media. The Checkpoint stock price prediction module provides an analysis of price elasticity to changes in media outlook on Checkpoint Therapeutics over a specific investment horizon. Using Checkpoint Therapeutics hype-based prediction, you can estimate the value of Checkpoint Therapeutics from the perspective of Checkpoint Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Checkpoint Therapeutics using Checkpoint Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Checkpoint using crowd psychology based on the activity and movement of Checkpoint Therapeutics' stock price.

Checkpoint Therapeutics Implied Volatility

    
  0.0  
Checkpoint Therapeutics' implied volatility exposes the market's sentiment of Checkpoint Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Checkpoint Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Checkpoint Therapeutics stock will not fluctuate a lot when Checkpoint Therapeutics' options are near their expiration.
This module is based on analyzing investor sentiment around taking a position in Checkpoint Therapeutics. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Checkpoint Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Checkpoint because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Checkpoint Therapeutics after-hype prediction price

    
  USD 1.58  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Checkpoint Therapeutics Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Checkpoint Stock please use our How to Invest in Checkpoint Therapeutics guide.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Checkpoint Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
1.427.0710.46
Details
Naive
Forecast
LowNextHigh
0.031.604.98
Details
4 Analysts
Consensus
LowTargetHigh
21.2923.4025.97
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.37-0.27-0.18
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Checkpoint Therapeutics. Your research has to be compared to or analyzed against Checkpoint Therapeutics' peers to derive any actionable benefits. When done correctly, Checkpoint Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Checkpoint Therapeutics.

Checkpoint Therapeutics After-Hype Price Prediction Density Analysis

As far as predicting the price of Checkpoint Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Checkpoint Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Checkpoint Therapeutics, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Checkpoint Therapeutics Estimiated After-Hype Price Volatility

In the context of predicting Checkpoint Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Checkpoint Therapeutics' historical news coverage. Checkpoint Therapeutics' after-hype downside and upside margins for the prediction period are 0.08 and 4.97, respectively. We have considered Checkpoint Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
1.58
1.58
After-hype Price
4.97
Upside
Checkpoint Therapeutics is slightly risky at this time. Analysis and calculation of next after-hype price of Checkpoint Therapeutics is based on 3 months time horizon.

Checkpoint Therapeutics Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Checkpoint Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Checkpoint Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Checkpoint Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.19 
3.39
 0.00  
  0.32 
11 Events / Month
11 Events / Month
In about 11 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
1.58
1.58
0.00 
33,900  
Notes

Checkpoint Therapeutics Hype Timeline

Checkpoint Therapeutics is currently traded for 1.58. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.32. Checkpoint is projected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is projected to be very small, whereas the daily expected return is currently at -0.19%. %. The volatility of related hype on Checkpoint Therapeutics is about 199.41%, with the expected price after the next announcement by competition of 1.90. About 15.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 3.17. Checkpoint Therapeutics had not issued any dividends in recent years. The entity had 1:10 split on the 6th of December 2022. Given the investment horizon of 90 days the next projected press release will be in about 11 days.
Check out Checkpoint Therapeutics Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Checkpoint Stock please use our How to Invest in Checkpoint Therapeutics guide.

Checkpoint Therapeutics Related Hype Analysis

Having access to credible news sources related to Checkpoint Therapeutics' direct competition is more important than ever and may enhance your ability to predict Checkpoint Therapeutics' future price movements. Getting to know how Checkpoint Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Checkpoint Therapeutics may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
MBIOMustang Bio(0.01)7 per month 0.00 (0.29) 8.57 (19.61) 36.13 
RVPHReviva Pharmaceuticals Holdings 0.05 7 per month 0.00 (0.06) 7.31 (7.79) 32.56 
FBIOPFortress Biotech Pref 0.00 0 per month 3.43  0.10  5.75 (5.12) 22.88 
KODKodiak Sciences(0.94)8 per month 7.57 (0.01) 11.89 (10.92) 45.41 
FBIOFortress Biotech(0.02)9 per month 0.00 (0.02) 10.10 (7.03) 24.66 
ATXIAvenue Therapeutics 11.48 7 per month 0.00 (0.12) 10.09 (15.62) 53.57 
PIRSPieris Pharmaceuticals 15.31 5 per month 0.00 (0.07) 5.19 (5.42) 33.39 
ALRNAileron Therapeutics(0.30)8 per month 0.00 (0.01) 9.54 (9.58) 42.14 
CTMXCytomX Therapeutics 0.02 9 per month 3.28  0.12  10.00 (7.84) 50.71 
TILInstil Bio 0.21 8 per month 0.00 (0.05) 3.34 (3.60) 9.17 
NLTXNeoleukin Therapeutics(0.12)2 per month 0.00 (0.03) 6.67 (5.67) 15.97 
SPROSpero Therapeutics 0.06 9 per month 3.23  0.02  4.82 (5.59) 16.20 
ASMBAssembly Biosciences(0.75)6 per month 3.64  0.01  5.32 (4.67) 17.67 
ACHLAchilles Therapeutics PLC 0.03 9 per month 0.00 (0.01) 9.56 (9.02) 38.89 
CUECue Biopharma(0.04)8 per month 0.00 (0.05) 10.27 (6.86) 33.28 
MDNAMedicenna TherapeuticsCorp(0.02)3 per month 6.14  0.04  12.82 (11.11) 60.35 
XOMAOXOMA Corporation 0.00 0 per month 0.46 (0.03) 0.96 (0.78) 2.76 
ZIVOZivo Bioscience 7.17 2 per month 0.00 (0.49) 9.67 (14.29) 32.07 
LUMOLumos Pharma 0.17 7 per month 2.80  0.03  5.35 (3.81) 17.51 

Checkpoint Therapeutics Additional Predictive Modules

Most predictive techniques to examine Checkpoint price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Checkpoint using various technical indicators. When you analyze Checkpoint charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Checkpoint Therapeutics Predictive Indicators

The successful prediction of Checkpoint Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Checkpoint Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Checkpoint Therapeutics based on analysis of Checkpoint Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Checkpoint Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Checkpoint Therapeutics's related companies.
 2021 2023 (projected)
Payables Turnover2.824.64
Days Of Inventory On Hand7.0E-68.0E-6

Story Coverage note for Checkpoint Therapeutics

The number of cover stories for Checkpoint Therapeutics depends on current market conditions and Checkpoint Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Checkpoint Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Checkpoint Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Checkpoint Therapeutics Short Properties

Checkpoint Therapeutics' future price predictability will typically decrease when Checkpoint Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Checkpoint Therapeutics often depends not only on the future outlook of the potential Checkpoint Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Checkpoint Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding18.7 M
Cash And Short Term Investments4.9 M
When determining whether Checkpoint Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Checkpoint Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Checkpoint Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Checkpoint Therapeutics Stock:
Check out Checkpoint Therapeutics Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Checkpoint Stock please use our How to Invest in Checkpoint Therapeutics guide.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for Checkpoint Stock analysis

When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Is Checkpoint Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Checkpoint Therapeutics. If investors know Checkpoint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Checkpoint Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.17)
Revenue Per Share
0.004
Quarterly Revenue Growth
(0.92)
Return On Assets
(3.49)
Return On Equity
(12.20)
The market value of Checkpoint Therapeutics is measured differently than its book value, which is the value of Checkpoint that is recorded on the company's balance sheet. Investors also form their own opinion of Checkpoint Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Checkpoint Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Checkpoint Therapeutics' market value can be influenced by many factors that don't directly affect Checkpoint Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Checkpoint Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Checkpoint Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Checkpoint Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.